Replies to post #98896 on DD Support Board and Research Team

[janice shell]

Fortunately not many people put everything into one stock. Most do understand that diversification is important. Sure, there're exceptions. If you'd bet it all on Berkshire Hathaway in the mid 60s, or Apple in the 90s, you'd be sitting pretty now. But it's exceptions that prove the rule.

Most companies have ups and downs, and some that were once great eventually crashed and burned. Consider Polaroid.

There's a reason officers and directors of companies, even exchange-listed high flyers, sell some of their own stock on a regular basis. It's because they recognize the importance of diversification. Anything can happen.

[coinsguy]

Hard to imagine that anyone would be gleeful to see shareholders get creamed so devastatingly as to lead to something like this, but that is exactly what some sound like around here. This is what must be taken into account when one considers "more good than harm". There is a human side that must be considered, not just points of law.

[Realityhurts]

I genuinely hope that the post is false because, it is tragic if true.

Awful that his son would go from being fine to committing suicide over the span of a few days due to paper $ losses in a stock.

The stock is still up post RS. The only way to incur serious losses was if one purchased it last week.

[BEANPOLE]

My deepest sympathies to the family and may the young man RIP.

[DragonBear]

Very sad report by a poster on the AVXL board.

If one is going to place a huge bet on 1 stock, ya better be prepared to ride it down before up. Don't have the stomach, then diversify. Or risk only what Zofran can keep down. Yes, Shorts will attack a new over valued stock. Welcome to the NAS. Anyone who bought at $12-$14, probably would feel pressure.

Apparently the stock has fallen over 50% since moving to the NAS. A common occurrence for many stocks back in 2008. The stock hit a peak on 03-Nov. The IHUB forum is blaming a "The Street" report as inaccurate. Actually it's accurate. The Phase 2A study is a dose tolerance study, nothing more. No negative control arm. They are a long ways off in proving efficacy.

Anyone predicting $40-65 for a $6 stock can happen at any time isn't being realistic in their expectations. Especially when the current Phase should've been labelled as Phase 1. Don't know how the FDA allowed that to happen. Successful Phase 2 (effect on a limited number of participants including dose titration) might get a $6 biotech startup to $12. Saw one happen in just the last week. I missed that boat, or was it ignored that boat? Sigh.

Whether the drug will pan out is yet to be seen. I suspicion synergizing with Aricept will be a loser, since Aricept itself isn't that great for ALZ. Trying to find a cure for ALZ makes for good headlines, but lousy results.

[Zorax]

Sorry if there's an aura of doubt. I would submit that a devastated Father just doesn't post to a stock chat board less than 30 minutes of learning his son committed suicide. Does this sound like something important on ones mind just minutes of learning your son is gone?

Plus he posted less than a month.